BLA 125319 · Novartis Pharms
Ilaris
Canakinumab · Subcutaneous
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Nov 1, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Jun 17, 2009
Approved uses
8
Original approval plus efficacy supplements
Registered trials
106
36 Phase 3, 8 recruiting
FAERS reports
10,910
5,167 serious, 489 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 8, 2026.
ILARIS is an interleukin-1β blocker indicated for the treatment of: • Periodic Fever Syndromes ( 1.1 ): - Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familial Cold Auto-inflammatory Syndrome (FCAS) ◾ Muckle-Wells Syndrome (MWS) - Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients - Hyperimmunoglobulin D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients - Familial Mediterranean Fever (FMF) in adult and pediatric patients • Active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older ( 1.2 ) • Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate ( 1.3 ) 1.1 Periodic Fever Syndromes ILARIS ® (canakinumab) is an interleukin-1β (IL-1β) blocker indicated for the treatment of the following autoinflammatory Periodic Fever Syndromes: Cryopyrin-Associated Periodic Syndromes (CAPS) ILARIS is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and pediatric patients 4 years of age and older, including: Familial Cold Autoinflammatory Syndrome (FCAS) Muckle-Wells Syndrome (MWS) Tumor Necrosis Factor Receptor (TNF) Associated Periodic Syndrome (TRAPS) ILARIS is indicated for the treatment of Tumor Necrosis Factor (TNF) Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients. Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) ILARIS is indicated for the treatment of...
Mechanism: Canakinumab is a human monoclonal anti-human IL-1β antibody of the IgG1/κ isotype. Canakinumab binds to human IL-1β and neutralizes its activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1α or IL-1 receptor antagonist (IL-1ra). CAPS refer to rare genetic syndromes generally caused by mutations in the NLRP-3 [nucleotide-binding domain, leucine rich family (NLR), pyrin domain containing 3] gene (also known as Cold-Induced Autoinflammatory Syndrome-1 [CIAS1]). CAPS disorders are inherited in an autosomal dominant pattern with male and female offspring equally...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 25, 2023 Supplement 107 · Efficacy LetterLabel
- Jun 16, 2020 Supplement 97 · Efficacy · priority review OrphanLetterLabel
- Sep 23, 2016 Supplement 85 · Efficacy · priority review Breakthrough therapyOrphanLabelLetterReview
- Sep 23, 2016 Supplement 86 · Efficacy · priority review Breakthrough therapyOrphanLabelLetterReview
- Sep 23, 2016 Supplement 87 · Efficacy · priority review Breakthrough therapyOrphanLabelLetterReview
- Jul 21, 2016 Supplement 84 · Efficacy OrphanLabelLetter
- May 9, 2013 Supplement 62 · Efficacy · priority review OrphanLabelLetter
- Jun 17, 2009 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanReviewSummary ReviewLabel
1 products under this application
- ILARIS · CANAKINUMAB 180MG · INJECTABLE, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Canakinumab" as an intervention, any sponsor and status, largest first.
- Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01327846 · 10,066 participants · Start Apr 11, 2011 · Primary completion Mar 28, 2017
Drug: Canakinumab; Placebo and 1 more · For: Atherosclerosis
Sites: Athens, Alabama; Birmingham, Alabama; Fairhope, Alabama · 1,131 sites in all
- Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-APivotal-lookingTerminated
Novartis PharmaceuticalsNovartis (NVS)
NCT03447769 · 1,382 participants · Start Mar 16, 2018 · Primary completion Mar 17, 2022
Drug: Canakinumab; Placebo · For: Non-Small Cell Lung Cancer
Sites: Fayetteville, Arkansas; Los Alamitos, California; Los Angeles, California · 283 sites in all
- COVID-19 VaccinE Response in Rheumatology PatientsPivotal-lookingCompleted
Jeffrey CurtisAcademic, hospital or other
NCT05080218 · 841 participants · Start Nov 15, 2021 · Primary completion Apr 4, 2024
Drug: Upadacitinib; Abatacept and 6 more · For: Rheumatoid Arthritis; Psoriatic Arthritis; Spondylarthritis
Sites: Birmingham, Alabama; Hoover, Alabama; Phoenix, Arizona · 8 sites in all
- Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC SubjectsPivotal-lookingTerminated
Novartis PharmaceuticalsNovartis (NVS)
NCT03631199 · 673 participants · Start Dec 21, 2018 · Primary completion Aug 9, 2021
Drug: canakinumab; canakinumab-matching placebo and 6 more · For: Non-small Cell Lung Cancer
Sites: Long Beach, California; Los Angeles, California; Orlando, Florida · 152 sites in all
- Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic PatientsPivotal-lookingTerminated
NovartisNovartis (NVS)
NCT00900146 · 556 participants · Start Apr 2009 · Primary completion Nov 2010
Drug: Canakinumab; Metformin and 1 more · For: Diabetes Mellitus, Type 2
Sites: Phoenix, Arizona; La Jolla, California; Los Gatos, California · 106 sites in all
- A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic CancerPivotal-lookingCompleted
Pancreatic Cancer Action NetworkAcademic, hospital or other
NCT04229004 · 502 participants · Start Jan 31, 2020 · Primary completion Feb 5, 2025
Drug: Gemcitabine combined with nab-paclitaxel; Dose -mFOLFIRINOX and 3 more · For: Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma
Sites: La Jolla, California; Los Angeles, California; San Francisco, California · 25 sites in all
- Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced PneumoniaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT04362813 · 454 participants · Start Apr 30, 2020 · Primary completion Sep 16, 2020
Drug: Canakinumab; Placebo · For: Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia
Sites: Birmingham, Alabama; Glendale, California; San Francisco, California · 39 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT00819585 · 432 participants · Start Dec 2008 · Primary completion Aug 2010
Drug: Canakinumab; Colchicine and 3 more · For: Gout
Sites: Huntington Beach, California; San Diego, California; Jupiter, Florida · 89 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pyrexia1,442
- drug ineffective1,242
- inappropriate schedule of drug administration1,242
- inappropriate schedule of product administration966
- pain946
- condition aggravated876
- off label use751
- malaise731
- arthralgia613
- rash571
- incorrect dose administered506
- joint swelling492
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2010 | 9 |
| 2011 | 61 |
| 2012 | 188 |
| 2013 | 98 |
| 2014 | 143 |
| 2015 | 493 |
| 2016 | 956 |
| 2017 | 1,421 |
| 2018 | 1,130 |
| 2019 | 985 |
| 2020 | 1,206 |
| 2021 | 734 |
| 2022 | 1,021 |
| 2023 | 972 |
| 2024 | 632 |
| 2025 | 521 |
| 2026 | 339 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ilaris (Canakinumab/PF)
2024 spending
$55.7M
Beneficiaries
379
1,975 claims
Per beneficiary
$147,058
$18,603.17 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $17,711,823 |
| 2021 | $25,811,119 |
| 2022 | $33,488,914 |
| 2023 | $39,279,713 |
| 2024 | $55,735,087 |
Part B: Ilaris (Canakinumab/PF) · HCPCS J0638
2024 spending
$21.4M
Beneficiaries
225
902 claims
Per beneficiary
$95,067
2024 ASP limit $125.79 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,385,523 |
| 2021 | $4,056,681 |
| 2022 | $7,130,946 |
| 2023 | $12,350,189 |
| 2024 | $21,390,124 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Ridker PM, Everett BM, Thuren T, et al. · N Engl J Med 2017 · Multicenter Study, Randomized Controlled Trial
- A bibliometric analysis of immunotherapy for atherosclerosis: trends and hotspots prediction.
Wang JH, Pan GR, Jiang L · Front Immunol 2024 · Systematic Review, Research Support, Non-U.S. Gov't
- Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders.
Arnold DD, Yalamanoglu A, Boyman O · Front Immunol 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.
De Benedetti F, Gattorno M, Anton J, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and safety of biologic drugs in Still's disease: a systematic review and network meta-analysis of randomized controlled trials.
Kilic B, Ozturk A, Karup S, et al. · Rheumatology (Oxford) 2025 · Systematic Review, Network Meta-Analysis
- Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
Ridker PM, Everett BM, Pradhan A, et al. · N Engl J Med 2019 · Multicenter Study, Randomized Controlled Trial
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.